Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

Bono et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d69ac1bd542bb5f5029c71 — DOI: https://doi.org/10.1158/1078-0432.ccr-08-0872

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor· 2007 · 17 citations
2. Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer· 2007 · 21 citations
3. The validation of surrogate endpoints in meta-analyses of randomized experiments· 2000 · 599 citations
4. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases· 2004 · 38 citations
5. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group· 1999 · 983 citations